Analysts Issue Forecasts for Organogenesis FY2025 Earnings

Organogenesis Holdings Inc. (NASDAQ:ORGO) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Organogenesis in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn forecasts that the company will post earnings per share of ($0.08) for the year. The consensus estimate for Organogenesis’ current full-year earnings is ($0.07) per share.

Organogenesis Price Performance

Shares of NASDAQ ORGO opened at $3.53 on Thursday. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $443.83 million, a PE ratio of -58.83 and a beta of 1.77. The stock’s 50 day moving average price is $3.48 and its 200-day moving average price is $3.11. Organogenesis has a twelve month low of $2.16 and a twelve month high of $4.57.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.11. The business had revenue of $115.18 million for the quarter, compared to analysts’ expectations of $109.59 million. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. During the same period in the previous year, the company earned $0.02 earnings per share.

Insiders Place Their Bets

In other news, CEO Gary S. Gillheeney sold 41,052 shares of Organogenesis stock in a transaction on Monday, December 9th. The stock was sold at an average price of $3.52, for a total transaction of $144,503.04. Following the sale, the chief executive officer now directly owns 3,359,726 shares in the company, valued at $11,826,235.52. The trade was a 1.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last quarter, insiders have sold 278,116 shares of company stock valued at $991,190. Insiders own 36.90% of the company’s stock.

Institutional Trading of Organogenesis

Hedge funds have recently added to or reduced their stakes in the stock. Captrust Financial Advisors purchased a new stake in shares of Organogenesis during the 3rd quarter worth approximately $36,000. Intech Investment Management LLC purchased a new stake in Organogenesis in the third quarter worth $43,000. Pallas Capital Advisors LLC lifted its position in shares of Organogenesis by 70.8% during the 3rd quarter. Pallas Capital Advisors LLC now owns 21,823 shares of the company’s stock valued at $63,000 after buying an additional 9,048 shares during the last quarter. Mackenzie Financial Corp grew its stake in shares of Organogenesis by 46.1% during the 2nd quarter. Mackenzie Financial Corp now owns 24,328 shares of the company’s stock worth $68,000 after acquiring an additional 7,678 shares during the period. Finally, SG Americas Securities LLC purchased a new stake in Organogenesis in the 3rd quarter worth about $72,000. Institutional investors own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.